ARGX
argenx NV ADR
NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY
$776.02
+0.13% today
Updated 2026-04-29
Market cap
$48.85B
P/E ratio
40.03
P/S ratio
11.53x
EPS (TTM)
$19.53
Dividend yield
—
52W range
$510 – $935
Volume
0.3M
argenx NV ADR (ARGX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
30.50%
Operating margin
27.40%
ROE
20.20%
ROA
8.86%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $1.46M | $-4.49M | 100.00% | -323.59% | -308.02% |
| 2012 | $2.18M | $-12.83M | 100.00% | -608.93% | -587.54% |
| 2013 | $3.70M | $-8.47M | 72.41% | -232.70% | -229.00% |
| 2014 | $4.57M | $-12.54M | 100.00% | -286.05% | -274.62% |
| 2015 | $7.49M | $-16.74M | 100.00% | -227.69% | -223.42% |
| 2016 | $15.47M | $-22.48M | 100.00% | -145.55% | -145.27% |
| 2017 | $43.69M | $-33.68M | 100.00% | -62.98% | -77.10% |
| 2018 | $24.57M | $-76.23M | 100.00% | -381.02% | -310.22% |
| 2019 | $78.46M | $-181.21M | 100.00% | -253.49% | -230.95% |
| 2020 | $41.24M | $-608.46M | 100.00% | -1,158.06% | -1,475.29% |
| 2021 | $497.28M | $-407.63M | 100.00% | -70.13% | -81.97% |
| 2022 | $410.75M | $-709.59M | 92.83% | -175.37% | -172.76% |
| 2023 | $1.23B | $-295.05M | 90.39% | -34.66% | -24.06% |
| 2024 | $2.19B | $833.04M | 89.62% | -0.99% | 38.03% |
| 2025 | $4.16B | $1.30B | 89.14% | 23.35% | 31.12% |